BlossomHill Therapeutics (BLSM) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $13.94, -6.94% vs the prior close of $14.98.
- Volume 293.11K shares, 1.2x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
BLSM slides 6.9% to $13.94, a 1-month low, 5 down days in a row. Closed at $13.94, -6.94% vs the prior close of $14.98. Day range $13.31–$14.79, opened at $14.79.
BLSM daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — BLSM slides 6.9% to $13.94, a 1-month low, 5 down days in a row
- Closed at $13.94, -6.94% vs the prior close of $14.98. Day range $13.31–$14.79, opened at $14.79.
- Volume was 293.11K shares, 1.2x its 50-day average of 248.62K.
- Price is -27.3% vs its 50-day average ($19.17).
- 52-week range $13.31–$27.99; today's close sits at 4% of that range, 50.2% below the 52-week high.
- That makes 5 straight losses.
Oct 15, 2026 — BLSM dips 1.8% to $14.98, a 1-month low, 4 down days in a row
- Closed at $14.98, -1.83% vs the prior close of $15.26. Day range $14.70–$15.53, opened at $15.17.
- Volume was 176.50K shares, 0.7x its 50-day average of 250.12K.
- 52-week range $14.70–$27.99; today's close sits at 2% of that range, 46.5% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — BLSM dips 1.4% to $15.26, a 1-month low, 3 down days in a row
- Closed at $15.26, -1.42% vs the prior close of $15.48. Day range $14.77–$15.84, opened at $15.39.
- Volume was 170.20K shares, 0.7x its 50-day average of 251.82K.
- 52-week range $14.77–$27.99; today's close sits at 4% of that range, 45.5% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — BLSM slides 10.4% to $15.48, a 1-month low
- Closed at $15.48, -10.36% vs the prior close of $17.27. Day range $15.35–$17.91, opened at $17.25.
- Volume was 118.60K shares, 0.5x its 50-day average of 254.72K — lighter than usual.
- 52-week range $15.25–$27.99; today's close sits at 2% of that range, 44.7% below the 52-week high.
Oct 12, 2026 — BLSM dips 1.2% to $17.27
- Closed at $17.27, -1.20% vs the prior close of $17.48. Day range $16.93–$18.22, opened at $17.40.
- Volume was 91.10K shares, 0.4x its 50-day average of 258.35K — lighter than usual.
- 52-week range $15.25–$27.99; today's close sits at 16% of that range, 38.3% below the 52-week high.
Oct 9, 2026 — BLSM jumps 3.6% to $17.48
- Closed at $17.48, +3.55% vs the prior close of $16.88. Day range $16.68–$17.77, opened at $16.80.
- Volume was 131.80K shares, 0.5x its 50-day average of 261.23K — lighter than usual.
- 52-week range $15.25–$27.99; today's close sits at 18% of that range, 37.5% below the 52-week high.
Oct 8, 2026 — BLSM rises 1.6% to $16.88
- Closed at $16.88, +1.63% vs the prior close of $16.61. Day range $16.18–$17.28, opened at $16.52.
- Volume was 165.20K shares, 0.6x its 50-day average of 263.46K.
- 52-week range $15.25–$27.99; today's close sits at 13% of that range, 39.7% below the 52-week high.
Oct 7, 2026 — BLSM slides 3.9% to $16.61, a 1-month low
- Closed at $16.61, -3.93% vs the prior close of $17.29. Day range $16.12–$17.67, opened at $17.17.
- Volume was 253.80K shares, 1.0x its 50-day average of 263.69K.
- 52-week range $15.25–$27.99; today's close sits at 11% of that range, 40.7% below the 52-week high.
Oct 6, 2026 — BLSM slides 13.3% to $17.29, a 1-month low
- Closed at $17.29, -13.29% vs the prior close of $19.94. Day range $17.06–$20.06, opened at $20.06.
- Volume was 247.40K shares, 0.9x its 50-day average of 264.09K.
- 52-week range $15.25–$27.99; today's close sits at 16% of that range, 38.2% below the 52-week high.
Oct 5, 2026 — BLSM rises 1.3% to $19.94
- Closed at $19.94, +1.27% vs the prior close of $19.69. Day range $19.06–$20.11, opened at $19.72.
- Volume was 201.50K shares, 0.8x its 50-day average of 265.65K.
- 52-week range $15.25–$27.99; today's close sits at 37% of that range, 28.8% below the 52-week high.
Oct 2, 2026 — BLSM jumps 5.9% to $19.69
- Closed at $19.69, +5.92% vs the prior close of $18.59. Day range $18.27–$19.86, opened at $18.33.
- Volume was 169.30K shares, 0.6x its 50-day average of 268.12K.
- 52-week range $15.25–$27.99; today's close sits at 35% of that range, 29.7% below the 52-week high.
BLSM latest news & SEC filings
Every SEC filing by or about BLSM in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 18, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$23.76M (prior year -$13.24M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$8.75 (prior year -$5.51) (loss widened vs Jun 30, 2025)
Sep 18, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Sep 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 18, 2026 · Form SCHEDULE 13D — Activist-style stake (13D)
Activist-style stake (13D) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 17, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13D — Activist-style stake (13D)
Activist-style stake (13D) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gordon Carl L bought 625,000 shares at $16.00 (≈$10.00M) on Aug 10, 2026
- Gordon Carl L bought 625,000 shares at $16.00 (≈$10.00M) on Aug 10, 2026
- Gordon Carl L bought 625,000 shares at $16.00 (≈$10.00M) on Aug 10, 2026
- Gordon Carl L bought 625,000 shares at $16.00 (≈$10.00M) on Aug 10, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 12, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Orbimed Capital Gp Viii Llc bought 625,000 shares at $16.00 (≈$10.00M) on Aug 10, 2026
- Orbimed Capital Gp Viii Llc bought 625,000 shares at $16.00 (≈$10.00M) on Aug 10, 2026
- Orbimed Advisors Llc bought 625,000 shares at $16.00 (≈$10.00M) on Aug 10, 2026
- Orbimed Advisors Llc bought 625,000 shares at $16.00 (≈$10.00M) on Aug 10, 2026
- Orbimed Capital Gp Viii Llc bought 625,000 shares at $16.00 (≈$10.00M) on Aug 10, 2026
- Orbimed Capital Gp Viii Llc bought 625,000 shares at $16.00 (≈$10.00M) on Aug 10, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cormorant Private Healthcare Fund Vi, Lp bought 312,500 shares at $16.00 (≈$5.00M) on Aug 10, 2026
- Cormorant Private Healthcare Fund Vi, Lp bought 312,500 shares at $16.00 (≈$5.00M) on Aug 10, 2026
- Chen Bihua bought 312,500 shares at $16.00 (≈$5.00M) on Aug 10, 2026
- Chen Bihua bought 312,500 shares at $16.00 (≈$5.00M) on Aug 10, 2026
- Cormorant Private Healthcare Fund V Lp bought 312,500 shares at $16.00 (≈$5.00M) on Aug 10, 2026
- Cormorant Private Healthcare Fund V Lp bought 312,500 shares at $16.00 (≈$5.00M) on Aug 10, 2026
- …plus 3 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 10, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade BLSM
- Last results release: Sep 18, 2026 (8-K Item 2.02).
- How much it moves: over the last 20 sessions the average daily move was 5.30% (largest 13.3%). That is a volatile stock.
- Liquidity: about 206.67K shares (≈$2.88M) trade per day on average.
- 52-week position: $13.94 vs a range of $13.31–$27.99 (4% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Capital Gp Viii Llc Orbimed bought 625,000 shares on Aug 10, 2026.
- Latest filings: 10-Q Sep 18, 2026; 8-K Sep 18, 2026; 8-K Sep 15, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
BLSM market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 14.79 | 14.79 | 13.31 | 13.94 | 293.11K |
| Oct 15, 2026 | 15.17 | 15.53 | 14.70 | 14.98 | 176.50K |
| Oct 14, 2026 | 15.39 | 15.84 | 14.77 | 15.26 | 170.20K |
| Oct 13, 2026 | 17.25 | 17.91 | 15.35 | 15.48 | 118.60K |
| Oct 12, 2026 | 17.40 | 18.22 | 16.93 | 17.27 | 91.10K |
| Oct 9, 2026 | 16.80 | 17.77 | 16.68 | 17.48 | 131.80K |
| Oct 8, 2026 | 16.52 | 17.28 | 16.18 | 16.88 | 165.20K |
| Oct 7, 2026 | 17.17 | 17.67 | 16.12 | 16.61 | 253.80K |
| Oct 6, 2026 | 20.06 | 20.06 | 17.06 | 17.29 | 247.40K |
| Oct 5, 2026 | 19.72 | 20.11 | 19.06 | 19.94 | 201.50K |
| Oct 2, 2026 | 18.33 | 19.86 | 18.27 | 19.69 | 169.30K |
| Oct 1, 2026 | 18.49 | 19.74 | 18.46 | 18.59 | 152.60K |
| Sep 30, 2026 | 21.24 | 21.24 | 18.41 | 18.64 | 362.20K |
| Sep 29, 2026 | 21.17 | 22.20 | 20.70 | 21.37 | 228.50K |
| Sep 28, 2026 | 19.51 | 21.55 | 19.01 | 21.34 | 146.40K |
| Sep 25, 2026 | 20.46 | 21.03 | 19.33 | 19.75 | 203.10K |
| Sep 24, 2026 | 22.42 | 22.63 | 20.21 | 20.47 | 263.50K |
| Sep 23, 2026 | 25.30 | 25.81 | 21.88 | 22.34 | 219.40K |
| Sep 22, 2026 | 26.37 | 27.31 | 25.03 | 25.25 | 246.90K |
| Sep 21, 2026 | 26.09 | 27.99 | 25.12 | 26.80 | 292.20K |
About BlossomHill Therapeutics
BlossomHill Therapeutics (BLSM) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1839970.
BLSM board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Sundeep Agrawal | Director | Aug 10, 2026 |
| Bihua Chen | Director | Aug 10, 2026 |
| Jingrong Jean Cui | President and CEO | Aug 10, 2026 |
| Carl L Gordon | Director | Aug 12, 2026 |
| Sheila Gujrathi | Director | Aug 6, 2026 |
| Yishan Li | Executive Chairman | Aug 10, 2026 |
| Advisors Llc Orbimed | Director | Aug 12, 2026 |
| Capital Gp Viii Llc Orbimed | Director | Aug 12, 2026 |
| John P. Schmid | Director | Aug 10, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Jingrong Jean Cui | President and CEO | Aug 10, 2026 |
| Jason A Keyes | Chief Financial Officer | Aug 10, 2026 |
| Yishan Li | Executive Chairman | Aug 10, 2026 |
| Vincent Paul Liptak | General Counsel | Aug 10, 2026 |
| Geoffrey Raymond Oxnard | Chief Medical Officer | Aug 10, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 10, 2026 | Capital Gp Viii Llc Orbimed | Buy | 625,000 | $16.00 |
| Aug 10, 2026 | Capital Gp Viii Llc Orbimed | Buy | 625,000 | $16.00 |
| Aug 10, 2026 | Advisors Llc Orbimed | Buy | 625,000 | $16.00 |
| Aug 10, 2026 | Advisors Llc Orbimed | Buy | 625,000 | $16.00 |
| Aug 10, 2026 | Capital Gp Viii Llc Orbimed | Buy | 625,000 | $16.00 |
| Aug 10, 2026 | Capital Gp Viii Llc Orbimed | Buy | 625,000 | $16.00 |
| Aug 10, 2026 | Advisors Llc Orbimed | Buy | 625,000 | $16.00 |
| Aug 10, 2026 | Advisors Llc Orbimed | Buy | 625,000 | $16.00 |
| Aug 10, 2026 | Carl L Gordon | Buy | 625,000 | $16.00 |
| Aug 10, 2026 | Carl L Gordon | Buy | 625,000 | $16.00 |
| Aug 10, 2026 | Carl L Gordon | Buy | 625,000 | $16.00 |
| Aug 10, 2026 | Carl L Gordon | Buy | 625,000 | $16.00 |
| Aug 10, 2026 | Vincent Paul Liptak | Buy | 2,200 | $16.00 |
| Aug 10, 2026 | Vincent Paul Liptak | Buy | 2,200 | $16.00 |
| Aug 10, 2026 | Vincent Paul Liptak | Buy | 2,200 | $16.00 |
BLSM financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $124.13M, total liabilities $42.09M, cash $95.38M (as of Jun 30, 2026).
BLSM earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Sep 18, 2026 | 8-K Item 2.02 (results) | $25.74 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on BLSM
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.